GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced robust financial results for the third quarter ended December 31, 2025. The company achieved a topline revenue of INR 1023 Crores, marking an 8.1% growth. Profit After Tax (PAT) stood at INR 277 Crores, supported by strong cost discipline and improved EBITDA margins of 35.9%. Key portfolios, including General Medicines and Vaccines, drove this significant expansion.
Q3 FY26 Financial Performance Highlights
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) today announced its financial performance for the third quarter, which concluded on December 31, 2025. The company delivered a strong result, crossing the INR 1000 crore topline milestone with an 8.1% increase. Profitability remained well-managed through cost discipline.
Specifically, Revenue from Operations for the quarter reached INR 1023 Crores, while Profit After Tax (PAT) was reported at INR 277 Crores. A key driver of margin improvement was the growth in EBIDTA margins, which expanded by 520 basis points (bps) to 35.9%, attributed to better gross margins and operating leverage.
Segmental Growth Drivers
General Medicines and Vaccines
The General Medicines portfolio showed competitive performance, with its top five promoted brands, including flagship brands like Augmentin, Ceftum, and T-Bact, growing ahead of the market (Evolution Index [EI]>100*).
The Vaccines business experienced market share expansion, driven by sustained leadership in the self-pay private market for paediatric vaccines. Furthermore, Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted) is gaining adoption as awareness around preventive healthcare and adult immunisation increases among Healthcare Practitioners (HCPs).
Oncology Business Momentum
GSK India’s Oncology business, launched in August 2025, is gaining traction, led by specialized therapies Jemperli (Dostarlimab) and Zejula (Niraparib). The company made steady progress in reaching patients suffering from endometrial and recurrent ovarian cancer.
Results from the landmark Phase III trial, RUBY-1, which evaluated dostarlimab plus standard chemotherapy as a first-line treatment for primary advanced or recurrent endometrial cancer, demonstrated meaningful improvement in progression-free survival and overall survival. This reinforces the treatment’s benefit for this patient population.
Management Commentary
Bhushan Akshikar, Managing Director, GSK India, commented that the RUBY-1 trial has established a new paradigm in first-line treatment for endometrial cancer, simplifying decision-making for HCPs. He confirmed that despite broader macro environment challenges and efforts to mitigate internal supply issues, the implementation of the New Labour Codes 2025 did not have a material impact on the Company.
Source: BSE
